Novel and Emerging Therapies: Bempedoic Acid
Back to course
Video Transcription
statin therapy, which is really the backbone of lipid management these days. We talked about why patients may not be able to get to goals while using statin therapy.
And then we started to talk about two non-statins for which we have the outcome stata, that is ezetimibe and PCSK9 inhibitors. And now we have two more non-statins approved.
We heard about one of them in Clisteran, which is the siRNA. And now I'm gonna talk about the next non-statin, which was also approved by the FDA, and that is bampidoic acid.
These are my sources of research support and other disclosures. So this is really what I want to talk about. I'm gonna build on what was already discussed
by Dr. Gulati, Dr. Palantine, in terms of challenges with statin therapy. There are some challenges that we all face as clinicians, as well as our patients also face
related to statin therapy. So what are some of those? Some have been highlighted. I'm gonna just build on those a little bit more. Then the question is,
where could bampidoic acid fill that gap? But do remember that holds true for any non-statin therapy, whether that's ezetimibe, whether that's PCSK9 inhibitors,
whether that's in Clisteran. It's the same gap that these non-statin therapies are going to fill in, where statins may not be able to get us to where we want ourselves
in terms of our patients to get to. And then I'm gonna talk very quickly about the mechanism of action, efficacy and safety of bampidoic acid, what we need to know as clinicians,
Video Summary
In this video, the speaker discusses the challenges of achieving LDL cholesterol goals with statin therapy and introduces bempidoic acid as a potential non-statin therapy to fill this gap. They highlight that many patients on high-intensity statins still have elevated LDL cholesterol levels, making additional treatments necessary. The speaker explains that bempidoic acid is a prodrug that is activated in the liver, leading to LDL cholesterol reduction. It works through the same pathway as statins, but it has a different mechanism of action and may have a lower risk of musculoskeletal side effects. The speaker presents data from clinical trials showing the efficacy of bempidoic acid in reducing LDL cholesterol, especially when used in combination with ezetimibe. They also discuss potential side effects such as increased uric acid levels and tendon rupture. The speaker concludes by mentioning that ongoing outcome studies will provide more evidence about the effectiveness and safety of bempidoic acid.
LDL cholesterol goals
bempidoic acid
non-statin therapy
musculoskeletal side effects
clinical trials
Android App Download IOS App Download Powered By